+ Watch JAZZ
on My Watchlist
A specialty pharmaceutical company, which focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.
The market doesn't seem to be entirely comfortable with Jazz's bid to become a major pharma player through debt-funded acquisitions. Two years of steep upward momentum seems to have leveled off and the stock is well off the recent high of 52. Perhaps it hasn't completely forgotten that in 2009 Jazz almost winked out of existence with a 55 cent share price. Perhaps this company hasn't acquired all the tools in three short years to become a multinational pharmaceutical corporation with 500M in annual revenues. I'm skeptical as well. But I have to give the company credit for growing revenues of narcolepsy drug Xyrem far beyond the wildest speculation of the most rabidly optimistic analysts. Through cash and confidence, Xyrem has been the engine of Jazz's surge into the biotech elite. I'm weak when it comes to assessing the strength of acquisitions and future prospects of marketed drugs, but I'll give Jazz the benefit of the doubt on a downswing.
Just bought 150 shares at 55.41 for the Portefeuille collaboration.
Just sold 100 shares at 57.78 for a $237 profit for the Portefeuille collaboration.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions